Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2020

View Archived Issues

Ovarian organoids implicate oviducts

iPSC microtissue gives clues to heart disease

Estrogen and dopamine

Identification of a JAK inhibitor selectively targeting GI tissues for inflammatory bowel disease

A new ASK1 inhibitor presenting brain penetration

FDA accepts IND for phase I/II trial of Treadwell's HPK1 inhibitor CFI-402411

Brukinsa receives approval in China for patients with CLL/SLL and MCL

First patient data presented for PF-06804103 antibody-drug conjugate

Rgenix presents monotherapy dose-escalation data from phase I study of RGX-202

Phase II data reported from TreeTopp study of varlitinib plus capecitabine in BTC

FDA gives FSD Pharma permission to submit IND for phase IIa trial of FSD-201 for COVID-19

Ube Industries discloses cyclin-dependent kinase 7 inhibitors

Shanghai Ennova Biopharmaceutical patents neurotrophic tyrosine kinase receptor inhibitors

New MAP4K1 inhibitors discovered at Pfizer

New monobactam compounds presented by Nanjing Sanhome Pharmaceutical

Idorsia Pharmaceuticals identifies new Ox1-R and Ox2-R antagonists

Data questions arise for two major COVID-19 studies

Kezar reports updated phase Ib findings on KZR-616 in SLE

Maxinovel studies MAX-10181 for advanced solid tumors in first-in-human trial

Kadmon begins first-in-human study of KD-033 in metastatic or locally advanced solid tumors

European approval for Braftovi with cetuximab for BRAF V600E-mutant metastatic colorectal cancer

ImmuneOncia begins first-in-human study of IMC-002 for advanced solid tumors and lymphomas

Phase II dose defined in trial of CBL-0137 in patients with solid tumors

Pilot study evaluates DNAJB1-PRKACA peptide vaccine for fibrolamellar hepatocellular carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...